AnGes MG, Inc.-Product Pipeline Review-2015

AnGes MG, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC06867CDB
  • |
  • Pages: 43
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

AnGes MG, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'AnGes MG, Inc.-Product Pipeline Review-2015', provides an overview of the AnGes MG, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AnGes MG, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of AnGes MG, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of AnGes MG, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the AnGes MG, Inc.'s pipeline products

Reasons To Buy

Evaluate AnGes MG, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of AnGes MG, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the AnGes MG, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of AnGes MG, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of AnGes MG, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of AnGes MG, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

AnGes MG, Inc. Snapshot 5

AnGes MG, Inc. Overview 5

Key Information 5

Key Facts 5

AnGes MG, Inc.-Research and Development Overview 6

Key Therapeutic Areas 6

AnGes MG, Inc.-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

Pipeline Products-Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

AnGes MG, Inc.-Pipeline Products Glance 13

AnGes MG, Inc.-Late Stage Pipeline Products 13

Phase III Products/Combination Treatment Modalities 13

AnGes MG, Inc.-Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

AnGes MG, Inc.-Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

Discovery Products/Combination Treatment Modalities 17

AnGes MG, Inc.-Drug Profiles 18

beperminogene perplasmid 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

velimogene aliplasmid 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

S-414114 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

AG-30/5C 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Antibody for Ebola Virus Viral Infections 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

AnGes MG, Inc.-Pipeline Analysis 30

AnGes MG, Inc.-Pipeline Products by Target 30

AnGes MG, Inc.-Pipeline Products by Route of Administration 31

AnGes MG, Inc.-Pipeline Products by Molecule Type 32

AnGes MG, Inc.-Pipeline Products by Mechanism of Action 33

AnGes MG, Inc.-Recent Pipeline Updates 34

AnGes MG, Inc.-Dormant Projects 37

AnGes MG, Inc.-Discontinued Pipeline Products 38

Discontinued Pipeline Product Profiles 38

S-414114 38

AnGes MG, Inc.-Company Statement 39

AnGes MG, Inc.-Locations And Subsidiaries 40

Head Office 40

Other Locations & Subsidiaries 40

Appendix 42

Methodology 42

Coverage 42

Secondary Research 42

Primary Research 42

Expert Panel Validation 42

Contact Us 42

Disclaimer 43

List of Tables

AnGes MG, Inc., Key Information 5

AnGes MG, Inc., Key Facts 5

AnGes MG, Inc.-Pipeline by Indication, 2015 8

AnGes MG, Inc.-Pipeline by Stage of Development, 2015 9

AnGes MG, Inc.-Monotherapy Products in Pipeline, 2015 10

AnGes MG, Inc.-Partnered Products in Pipeline, 2015 11

AnGes MG, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 12

AnGes MG, Inc.-Phase III, 2015 13

AnGes MG, Inc.-Phase II, 2015 14

AnGes MG, Inc.-Phase I, 2015 15

AnGes MG, Inc.-Preclinical, 2015 16

AnGes MG, Inc.-Discovery, 2015 17

AnGes MG, Inc.-Pipeline by Target, 2015 30

AnGes MG, Inc.-Pipeline by Route of Administration, 2015 31

AnGes MG, Inc.-Pipeline by Molecule Type, 2015 32

AnGes MG, Inc.-Pipeline Products by Mechanism of Action, 2015 33

AnGes MG, Inc.-Recent Pipeline Updates, 2015 34

AnGes MG, Inc.-Dormant Developmental Projects,2015 37

AnGes MG, Inc.-Discontinued Pipeline Products, 2015 38

AnGes MG, Inc., Other Locations 40

AnGes MG, Inc., Subsidiaries 41

List of Figures

AnGes MG, Inc.-Pipeline by Top 10 Indication, 2015 7

AnGes MG, Inc.-Pipeline by Stage of Development, 2015 9

AnGes MG, Inc.-Monotherapy Products in Pipeline, 2015 10

AnGes MG, Inc.-Pipeline by Top 10 Target, 2015 30

AnGes MG, Inc.-Pipeline by Top 10 Route of Administration, 2015 31

AnGes MG, Inc.-Pipeline by Top 10 Molecule Type, 2015 32

AnGes MG, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of AnGes MG, Inc.; AnGes MG, Inc. - Key Therapeutics; AnGes MG, Inc. - Pipeline Overview and Promising Molecules; AnGes MG, Inc. - News; AnGes MG, Inc. - Latest Updates; AnGes MG, Inc. - Pipeline; AnGes MG, Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101985
Site License
USD 3000 INR 203970
Corporate User License
USD 4500 INR 305955



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]